There are numerous studies that compare different drugs in painful diabetic neuropathy (Bansal, 2009; Goldstein, 2005; Morello, 1999; Wernicke, 2007) but our study tries to make a comparison between all four drugs and evaluate the associated depression. The study shows the results of drug therapy for painful diabetic non-insulin-dependent neuropathy after 6 months. Four drugs are compared for their efficiency and also the global perception of change by the patients. Another aspect is the reduction in depression symptoms caused by unsuccessful therapy before using the drugs used in this study. The study shows how the drugs are similar in efficiency in pairs of two, one pair of drugs being more efficient than the other.
Objective
To compare the efficacy of pregabaline, gabapentine, sertraline and duloxetine in painful diabetic neuropathy (PDN).
Research design and methods
In this observational trial, 28 patients received pregabaline, gabapentine, sertraline and duloxetine orally once daily at bedtime for duloxetine and twice in the morning at 8 a clock and at the bedtime, each for 6 months with optional dose uptitration (divided in four groups, each group has 7 patients). Pain relief was measured by the patient's global assessment of efficacy, using a visual analogue scale (0-10). Treatment goals include restoring function and improving pain control. Patients were randomly selected, the common factor being the presence of PDN. Patients of either sex with type 2 diabetes, aged between 25 and 83 years, who were on stable glucoselowering medications during the preceding 3 month and who had PDN for at least 1 month were begin to be treated. Patients who had a pain score of >5, as assessed by visual analogue scale (VAS), were enrolled in our observation. PDN was confirmed by 1) the patient's medical history, 2) a diabetic neuropathy symptom and increased thresholds on the vibration perception test and monofilament test. Patients were excluded if they had any clinically significant or unstable medical or psychiatric illnesses. Patients with other causes of neuropathy; renal dysfunction , liver disease; psychiatric illness; uncontrolled hypertension; those taking anticonvulsants, antidepressants, local anaesthetics, or opioids; those who were pregnant; lactating women; or those being treated with any investigational drug within the last 30 days were excluded from this observation. All patients underwent 6 months of treatment with one drug and, at the end of 6 months, patients underwent clinical evaluation. One dose each of sertraline (50 or 100 mg once daily at bed time), gabapentine 400 mg three times daily with increasing the dose till 2400 mg, 75 pregabaline twice daily with increasing the dose till 300 mg two times a day and duloxetine (30 or 60 mg once daily at bed time) were used in the study. Treatment was started with the lowest dose of either drug, with fortnightly assessments with optional uptitration. The primary end point of the study was the reduction of the average pain score from initial results, as assessed by the patient's global assessment of efficacy by the VAS (0-10 points). Secondary end points included the 24-point Hamilton Rating Scale for Depression; and patient self-evaluation of overall change on the basis of patient global impression of change scale. Demographic characteristics were noted and all the parameters were measured before and after treatment with all four drugs and compared. Patients were not allowed any other pain medication.
Results and discussion
The study was conducted between January 2012 and June 2012. Population and samples: Total population was 28 participants randomly selected, divided into 4 groups of 7. Age varies between 25 and 83 years old, mean age 53.42 (SD 15.75), 12 male patients and 16 female patients, with duration of diabetes between 3 and 17 years, mean duration 3.90 (SD 11.03). Mean reduction of pain on VAS was calculated for each of the four groups and found a 13.08% improvement in the sertraline group, 14% improvement in gabapentine group, 57.25% improvement in pregabaline group and 73.83% improvement in duloxetine group. Differences between mean values of pain on VAS for each group were tested with t-test for paired samples and were found statistically significant and non-accidental. We based differences found on medication treatment for the past six months. Also, using same test there were no statistically significant differences found between results of sertraline and gabapentine groups, and not even between pregabaline and duloxetine groups, meaning that sertraline showed similar efficiency with gabapentine and pregabaline showed similar efficiency with duloxetine. Differences were however statistically significant between sertraline and pregabaline or duloxetine and also between gabapentine and pregabaline or duloxetine. Initial assessment showed normal distribution of scores. The 6 moths visit showed statistically significant reduction of depression score for all patients. Overall perception of change, being a patient self-reported measure, like the VAS, showed similar results as the VAS after data analysis.
Gathered data analysis

Conclusions
The current study compared the efficacy of duloxetine, pregabaline, gabapentine and sertraline in patients with PDN. All drugs demonstrated comparable efficacy as per the established pain-rating scales for PDN. Numerically, more patients have pain relief after duloxetine and pregabaline over sertraline and gabapentin. In the present observational study, pregabaline and duloxetine have similar efficacy and more than gabapentine and sertraline. More than 73% improvement in pain score was observed with duloxetine, and 57% with pregabaline. Improvement in pain was significant and as a result, a significant reduction in depression scores was also observed. The overall self-evaluation of patients is consistent with this result.
